Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (PRCT) delivers pioneering surgical robotics solutions for urologic care, with its AquaBeam and HYDROS systems redefining minimally invasive BPH treatment. This news hub provides investors and medical professionals with essential updates on PRCT's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative updates including FDA clearances, peer-reviewed study results, and financial performance reports. Our curated collection features official press releases on product innovations, partnership announcements, and clinical trial outcomes backed by PRCT's extensive clinical evidence base.
Stay informed about developments in aquablation therapy technology, global market expansion efforts, and advancements in AI-driven surgical planning. Content spans regulatory filings, executive leadership updates, and analyses of PRCT's growing body of clinical validation across urologic applications.
Bookmark this page for streamlined access to PROCEPT BioRobotics' latest achievements in surgical robotics. Check regularly for verified updates on technologies improving patient outcomes through precision tissue resection and image-guided procedures.
PROCEPT BioRobotics Corporation (PRCT) announced that United Healthcare updated its Prostate Surgeries and Interventions Policy Bulletin, confirming Aquablation therapy as medically necessary for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Effective June 1, 2023, this policy enhances accessibility for patients, potentially providing access to approximately 95% of men in the U.S. The Aquablation therapy employs an automated robotic system that uses heat-free waterjet technology, backed by successful FDA trials demonstrating its safety and efficacy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced an in-person investor event on April 28, 2023, during the American Urological Association Annual Meeting in Chicago. This event will feature remarks from key executives and a surgeon panel discussing the benefits of Aquablation therapy, which addresses benign prostatic hyperplasia (BPH). Attendees include CEO Reza Zadno and other senior executives. A live webcast of the event will be available on the company's website for at least 90 days. PROCEPT BioRobotics is focused on developing robotic systems for minimally invasive urologic surgery, with significant clinical evidence supporting its Aquablation therapy.
PROCEPT BioRobotics Corporation announced that its Aquablation Therapy for benign prostate hyperplasia (BPH) has received a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence (NICE) in the UK. The therapy is recognized as equally effective as traditional TURP, with clinical experts noting its innovative nature, ability to preserve sexual function, and potential to replace TURP. Aquablation is the first robotic surgical system to obtain a MIB, validating its safety and durability compared to TURP. PROCEPT BioRobotics emphasizes its commitment to advancing patient care through transformative urological solutions.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a leader in surgical robotics focused on urology, announced management will present at the Virtual Key Bank Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:45 p.m. Eastern Time. A live webcast will be available, with an archived recording for replay for 90 days. PROCEPT is renowned for its AquaBeam Robotic System, designed for minimally invasive urologic surgery, specifically targeting benign prostatic hyperplasia (BPH), which affects 40 million men in the U.S. The company boasts extensive clinical evidence supporting its Aquablation therapy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported significant financial growth for 2022, with total revenue reaching $75.0 million, a 118% increase from 2021. In Q4 2022 alone, revenue was $23.8 million, marking a 135% rise year-over-year. System and rental revenue for the U.S. hit $10.4 million, up 109%, while handpiece and consumable revenue soared by 202%. Despite a net loss of $28.2 million for the quarter, the company projects $125 million in revenue for 2023, reflecting a 67% growth forecast. Key factors driving growth include expansion in the sales team and increased market interest.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced that its management will present at the 43rd Annual Cowen Health Care Conference in Boston on March 7, 2023, at 12:50 p.m. Eastern Time. Interested parties can access a live webcast and an archived recording on the company’s website for at least 90 days following the event.
PROCEPT is recognized for its AquaBeam Robotic System, aimed at enhancing minimally invasive surgery for benign prostatic hyperplasia (BPH). Currently, BPH affects around 40 million men in the U.S., and PROCEPT's innovative Aquablation therapy is supported by extensive clinical evidence, including nine studies and over 100 peer-reviewed publications.
PROCEPT BioRobotics plans to report its fourth quarter and fiscal year 2022 financial results on February 28, 2023. Preliminary unaudited revenue for Q4 2022 is projected between $23.6 million and $23.8 million, significantly up from $10.1 million in Q4 2021. Total revenue for fiscal year 2022 is expected to be around $74.8 million to $75 million, reflecting a 117% growth year-over-year. The company emphasizes its commitment to advancing patient care in urology through innovative surgical solutions.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2023, at 9:45 a.m. Pacific Time. The event will feature a presentation by the company's management team. Interested parties can access a live webcast and an archived recording through the company’s website.
PROCEPT BioRobotics focuses on innovating surgical robotics for urology, specifically addressing benign prostatic hyperplasia (BPH) through its AquaBeam Robotic System, which is backed by extensive clinical evidence.
PROCEPT BioRobotics (Nasdaq: PRCT) reported a 135% increase in total revenue for Q3 2022, totaling $20.3 million compared to the same period last year. U.S. system revenue rose 95% to $9.8 million, while handpiece revenue surged 267% to $8.0 million. The company raised its 2022 revenue guidance to approximately $72.5 million, a 110% growth over 2021. However, net loss widened to $22.6 million and operating expenses increased to $32.3 million.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will release its third quarter financial results on November 3, 2022, after the market closes. A conference call with management will follow at 1:30 p.m. Pacific Time. Investors can join via webcast or phone. The company is focused on surgical robotics, specifically addressing benign prostatic hyperplasia (BPH) through the AquaBeam Robotic System, which has shown significant clinical evidence in improving patient outcomes. Information on the event will be accessible on their website and archived recordings will be available for 90 days.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
